Log in
Enquire now
‌

US Patent 9913901 Combination therapy for treating HER2-positive cancers

Patent 9913901 was granted and assigned to Merrimack Pharmaceuticals on March, 2018 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Patent Applicant
Merrimack Pharmaceuticals
Merrimack Pharmaceuticals
0
Current Assignee
Merrimack Pharmaceuticals
Merrimack Pharmaceuticals
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
99139010
Patent Inventor Names
Elena Geretti0
Victor Moyo0
Thomas Wickham0
Bart S. Hendriks0
Christopher W. Espelin0
Joseph G. Reynolds0
Date of Patent
March 13, 2018
0
Patent Application Number
146502500
Date Filed
December 3, 2013
0
Patent Primary Examiner
‌
Misook Yu
0
Patent abstract

Methods for treating cancer patients with HER2-positive tumors are disclosed. The methods comprise administering to a patient a therapeutically effective amount of a combination of (i) an anthracycline-loaded immunoliposome with a targeting moiety that is a first anti-HER2 antibody and (ii) an anti-cancer therapeutic comprising a second anti-HER2 antibody.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 9913901 Combination therapy for treating HER2-positive cancers

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us